Genetic Test for Medication Use

Adverse Drug Reactions Are The 4th Leading Cause Of Death In The United States

The prevalence of Adverse Drug Reactions (ADRs) in the United States is a major healthcare concern. ADRs occur even when the physician wrote the correct prescription and the patient took the medication properly! More money was spent on treating adverse drug reactions (an estimated $389 billion) than on prescription drugs themselves ($325 billion) in the U.S. in 2012.

Introducing PharmaRisk™ Extended, a one-time test that can help assess a patient's predisposition for a reaction to medication and help the physician tailor drug treatment / dosage to maximize therapeutic benefits and minimize adverse drug reactions.

PharmaRisk™ Extended is the most comprehensive pharmacogenetic test available. For example, using a saliva sample, we can analyze all the genes that metabolize commonly prescribed pain medications and show physicians exactly which drugs a patient will respond to best. Our test covers 102 genetic markers across 18 genes.

PharmaRisk™ Extended has proven application across all clinical practices, including:

• Internal Medicine                      • General Practice
• Psychiatry                                  • Cardiology
• Geriatrics                                   • Chronic Pain Management

Who should be tested?

• Pre-Operative Patients
• Cardiovascular Surgery candidates
• Surgery patients requiring pain medication
• Patients with a history of an adverse drug reaction
• Family history of thromboembolism
• Patients with known mental disease
• Patients using or planning to use Coumadin® or Plavix®
• Chronic use patients with multiple medications (4 or more)

Which genes are included in the PharmaRisk™ Extended Panel? Which types of drugs?

Genes Evaluated

Drug Class

Drugs Targeted (examples)

CYP2D6, OPRM1

Analgesics-Opioids

Codeine¨, Fentanyl, Hydrocodone, Morphine, Oxycodone, Tramadol (Ultram)

CYP2C9

Analgesices - NSAIDs

Celocoxib (Celebrex), Flurbiprofen (Ansaid), Piroxicam

CYP2D6, COMT

Anti-ADHD Agents

Atomexatine, Amphetamines (Adderall), dexmethylphenidate, Dextroamphetamine, Lisdexamfetamine, Methylphenidate

CYP2B6,COMT,OPRM1, DRD2

Antiaddictives

Bupropion (Wellbutrin), Methadone, Naltrexone

CYP2D6

Antiarrhythmic

Flecainide, Mexiletine, Propafenone

CYP2D6

Antidementia Agents

Donepezil, Galantamine

DYP2D6, CYP2C19

Antidepressants SSRIs

Citalopram (Celexa), Escitalopram, Desvenlafaxine, Duloxetine, Mirtazapine, Paroxetine (Paxil) Sertraline (Zoloft), Venlafaxine

CYP2D6, CYP2C19

Antidepressants TCAs

Amitriptyline¨ (Elavil), Clomipramine¨, Desipramine¨, Doxepin¨ (Silenor) Imipramine¨, Nortriptyline¨, Trimipramine¨

CYP2C9

Anti-diabetics

Blimepiride, Glipizide, Glyburide, Tolbutamide

CYP2D6

Antiemetics

Odansetron

CYP2C9

Antiepileptics

Phenytoin (Dilantin)

CYP2C19

Antifugals

Voriconazole

ABCG2, SLC01B1, CYP3A4, CYP3A5

Antihyperlipidemics

Atorvastatin (Lipitor), Simvastatin¨ (Zocor), Rosuvastatin (Crestor), Fluvastatin, Irbesartan, Lovastatin, Pravastatin

CYP2D6, CYP2C9

Antihypertensives

Carvedilol (Coreg), Metoprolol (Lopressor), Irbesartan, Nebivolol, Propranolol, Timolol

CYP2C19, CYP2C9, VKORC1, CYP3A5

Antiplatelets- Anticoagulants

Clopidogrel ¨(Plavix), Prasugrel (Effient), Warfarin¨, (Coumadrin)

CYP2D6, CYP1A2

Antipsychotic

Aripiprazole (Abilify), Clozapine, Haloperidol, Iloperidone, Olanzapine, Paliperidone, Perphenazine, Pimozide, Risperidone, Tetrabenazine, Thioridazine

CYP2C19, UGT2B15

Anxiolytics-Hypnotics

Diazepam (Valium), Clobazam (Onfi), Lorazepam, Oxazepam

CYP3A5

Immunosupressants

Tacrolimus

CYP2C19, CYP1A2

Muscle Relaxants

Carisoprodol, Tizanidine (Zanaflex)

CYP2C19

Proton Pump Inhibitors

Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole

CYP2D6, CYP3A5

Urologicals

Darifenacin, Fesoteradine, Tamsulosin, Tolterodine

 

                  ¨Drugs that have CPIC published genetic testing and/or dosing guidelines

 

Do your patients have genetic risk factors for thromboembolism?

PharmaRisk™ Extended includes genes to assess inherited risk for thrombosis:

  • Factor II and Factor V Leiden ----increased risk for thrombophilia
    • MTHFR ----elevated risk for hyperhomocysteinemia and CVD
           • Apolipoprotein E ----increased risk for hyperlipidemia

 

 

Try PharmaRisk Extended Today for the health of your patients and experience the difference of knowing in advance rather than dealing with unknown effects after the fact.

CALL TODAY FOR MORE INFORMATION: 248-497-1007

PharmaRisk Extended is a product of Affiliated Genetics and is offered as a service through Tools4Medicine, LLC.